Prognostic relevance of programmed death-ligand 1 expression and microsatellite status in small bowel adenocarcinoma

References

• Aparicio T, Zaanan A, Svrcek M, et al. Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment. Digest Liver Dis. 2014;46(2):97–104.
   Web of Science ®Google Scholar
• Bilimoria KY, Bentrem DJ, Wayne JD, et al. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg. 2009;249(1):63–71.
   PubMed Web of Science ®Google Scholar
• Sakae H, Kanzaki H, Nasu J, et al. The characteristics and outcomes of small bowel adenocarcinoma: a multicentre retrospective observational study. Br J Cancer. 2017;117(11):1607–1613.
   PubMed Web of Science ®Google Scholar
• Chen EY, Vaccaro GM. Small bowel adenocarcinoma. Clin Colon Rectal Surg. 2018;31(05):267–277.
   PubMed Web of Science ®Google Scholar
• Aparicio T, Svrcek M, Zaanan A, et al. Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study. Br J Cancer. 2013;109(12):3057–3066.
   PubMed Web of Science ®Google Scholar
• Wang X, Teng F, Kong L, et al. PD-L1 expression in human cancers and its association with clinical outcomes. OTT. 2016;9:5023–5039.
   Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–2520.
   PubMed Web of Science ®Google Scholar
• Hanninen UA, Katainen R, Tanskanen T, et al. Exome-wide somatic mutation characterization of small bowel adenocarcinoma. PLOS Genet. 2018;14(3):e1007200.
   PubMed Web of Science ®Google Scholar
• Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–213.
   PubMed Web of Science ®Google Scholar
• Quaas A, Heydt C, Waldschmidt D, et al. Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma. BMC Gastroenterol. 2019;19(1):21.
   PubMed Web of Science ®Google Scholar
• Chen J, Jiang CC, Jin L, et al. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol. 2016;27(3):409–416.
   PubMed Web of Science ®Google Scholar
• Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–5074.
   PubMed Web of Science ®Google Scholar
• Droeser RA, Hirt C, Viehl CT, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer (Oxford, England: 1990). 2013;49(9):2233–2242.
   PubMed Web of Science ®Google Scholar
• Ohigashi Y, Sho M, Yamada Y, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res. 2005;11(8):2947–2953.
   PubMed Web of Science ®Google Scholar
• Qing Y, Li Q, Ren T, et al. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Devel Ther. 2015;9:901–909.
   PubMed Web of Science ®Google Scholar
• Thota R, Gonzalez RS, Berlin J, et al. Could the PD-1 pathway be a potential target for treating small intestinal adenocarcinoma? Am J Clin Pathol. 2017;148(3):208–214.
   PubMed Web of Science ®Google Scholar
• Saraggi D, Galuppini F, Remo A, et al. PD-L1 overexpression in ampulla of Vater carcinoma and its pre-invasive lesions. Histopathology. 2017;71(3):470–474.
   PubMed Web of Science ®Google Scholar
• Velcheti V, Schalper KA, Carvajal DE, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest. 2014;94(1):107–116.
   PubMed Web of Science ®Google Scholar
• Yang CY, Lin MW, Chang YL, Wu CT, et al. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer (Oxford, England: 1990). 2014;50(7):1361–1369.
   PubMed Web of Science ®Google Scholar
• Bakaeen FG, Murr MM, Sarr MG, et al. What prognostic factors are important in duodenal adenocarcinoma? Arch Surg. 2000;135(6):635–641.
   PubMedGoogle Scholar
• Halfdanarson TR, McWilliams RR, Donohue JH, et al. A single-institution experience with 491 cases of small bowel adenocarcinoma. Am J Surg. 2010;199(6):797–803.
   PubMed Web of Science ®Google Scholar
• Poultsides GA, Huang LC, Cameron JL, et al. Duodenal adenocarcinoma: clinicopathologic analysis and implications for treatment. Ann Surg Oncol. 2012;19(6):1928–1935.
   PubMed Web of Science ®Google Scholar
• Sohn TA, Lillemoe KD, Cameron JL, et al. Adenocarcinoma of the duodenum: factors influencing long-term survival. J Gastrointest Surg. 1998;2(1):79–87.
   PubMedGoogle Scholar
• Dabaja BS, Suki D, Pro B, et al. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer. 2004;101(3):518–526.
   PubMed Web of Science ®Google Scholar
• Overman MJ, Hu CY, Wolff RA, et al. Prognostic value of lymph node evaluation in small bowel adenocarcinoma: analysis of the surveillance, epidemiology, and end results database. Cancer. 2010;116(23):5374–5382.
   PubMed Web of Science ®Google Scholar
• Zaanan A, Costes L, Gauthier M, et al. Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. Ann Oncol. 2010;21(9):1786–1793.
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Albacker LA, Hopkins AC, et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight. 2019;4(6):e126908.
   PubMed Web of Science ®Google Scholar
• Vanderwalde A, Spetzler D, Xiao N, et al. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Med. 2018;7(3):746–756.
   PubMed Web of Science ®Google Scholar
• Schrock AB, Devoe CE, McWilliams R, et al. Genomic profiling of small-bowel adenocarcinoma. JAMA Oncol. 2017;3(11):1546–1553.
   PubMed Web of Science ®Google Scholar
• Hause RJ, Pritchard CC, Shendure J, et al. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med. 2016;22(11):1342–1350.
   PubMed Web of Science ®Google Scholar
• Murphy KM, Zhang S, Geiger T, et al. Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers. J Mol Diagn: JMD. 2006;8(3):305–311.
   PubMed Web of Science ®Google Scholar
• Fornasarig M, Magris R, De Re V, et al. Molecular and pathological features of gastric cancer in lynch syndrome and familial adenomatous polyposis. IJMS. 2018;19(6):1682.
   Web of Science ®Google Scholar
• Wagner PL, Chen YT, Yantiss RK. Immunohistochemical and molecular features of sporadic and FAP-associated duodenal adenomas of the ampullary and nonampullary mucosa. Am J Surg Pathol. 2008;32(9):1388–1395.
   PubMed Web of Science ®Google Scholar